Apr 13, 2022, 08:45
Carbiotix (publ) ("Carbiotix" or "Company") announces today that the Company has completed the installation of the first CarbiAXOS production line in Bjuv, Sweden. The Company accessed the fully renovated production hall in November 2021 and, with the support of its engineering partner, has focused on installing the first 10-ton CarbiAXOS production line in the first quarter of 2022. Carbiotix will start up the production line at the end of April after several minor installations and inspections are completed and plans to have an opening ceremony for invited guests later in the second quarter to celebrate this key milestone. This first production line will initially provide CarbiAXOS for the upcoming medical food study, samples for customer testing and formulation work, and eventually products for sale.
Kristofer Cook, CEO of Carbiotix, comments
"I am very delighted to announce the completion of the installation of Carbiotix first CarbiAXOS production line. The renovation of the production hall and installation of the first 10-ton production line has taken more than nine months and has given both our engineering team and our partner useful experience. The completion of the first production line is one of three key milestones during 2022, the others of which include clarity on the GRAS Self Affirmation approval and CarbiAXOS launch timeline, and the first CarbiAXOS customer agreement.
I look forward to celebrating this key achievement with an opening ceremony later in the second quarter and quickly moving through start-up and process optimisation work in this same period. This first production line will provide CarbiAXOS for our type-2 diabetes medical food study with Lund University starting in the second quarter. Moreover, the production line will provide samples for customer testing and formulation work, and eventually products for sale upon completion of GRAS SA. I am very excited to be moving into this next phase in the Company’s development. This phase focused on the start and expansion of commercial sales, something that is dependent on scaling up CarbiAXOS production to meet a growing customer demand.”
This communication contains forward-looking statements, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as of the date they are made and are, by their nature, as is research and development work in the biotechnology segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios as described in this press release.
För ytterligare information, vänligen kontakta
Kristofer Cook, VD
Carbiotix AB (CRBX) (www.carbiotix.com) is an award-winning biotechnology company pioneering microbiome healthcare through a range of cost-effective gut health testing services and a portfolio of microbiome modulators covering prebiotic ingredients, medical foods and therapeutics.Go Back